News Releases

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms

News tagged ‘BreastCancer’ clear

  • Erica Mayer, MD, MPH, is a breast cancer expert at Dana-Farber. She says there are at least five simple ways women can reduce their risk of getting the disease.

Tags: BreastCancer, Genetics, Prevention

  • Breast cancer risk and prevention experts comment on new guidelines suggesting women ages 40 to 49 do not need regular breast cancer screenings.

Tags: BreastCancer

  • Practice-changing clinical research conducted at the Dana-Farber Cancer Institute Department of Biostatistics and Computational Biology was featured at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting Plenary Session.

Tags: BreastCancer, ProstateCancer

  • Researchers from Dana-Farber Cancer Institute will be presenting more than 70 studies at this year’s annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 29 – June 2, 2015.

Tags: chemotherapy, BreastCancer

  • Kornelia Polyak, MD, PhD, and colleagues identified a network of growth-spurring genes that drive stem-like breast cancer cells enriched in triple-negative breast tumors.

Tags: BreastCancer, Genomics

  • Younger women are more likely to be diagnosed with later-stage breast cancer, and treatment may affect fertility. Dana-Farber's specialized program addresses the unique needs of these patients.

Tags: BreastCancer

  • Susan G. Komen for the Cure, the world's largest grassroots network of breast cancer survivors and activists, has announced the appointment of Eric P. Winer, MD, a nationally known medical oncologist, researcher and educator from the Dana-Farber Cancer Institute and Harvard Medical Center, as its chief scientific advisor.

Tags: BreastCancer

  • Dana-Farber's Judy Garber, MD, MPH, an internationally recognized leader in clinical and translational research on breast cancer, has been elected to the Institute of Medicine.

Tags: BreastCancer, Honors, Genetics

  • Scientists from Brigham and Women's Hospital and Dana-Farber Cancer Institute and their colleagues have found a genetic marker that predicts which aggressive "triple negative" breast cancers and certain ovarian cancers will likely respond to platinum-based chemotherapies.

Tags: BasicResearch, BreastCancer, Genomics, OvarianCancer, GynecologicCancers

  • A combination of a "targeted" therapy and chemotherapy shrank metastatic brain tumors by at least 50 percent in one-fifth of patients with aggressive HER2-positive breast cancer, according to data presented by Dana-Farber investigators at the San Antonio Breast Cancer Symposium.

Tags: BreastCancer, BrainTumors

Showing 21-30 of 55 items